Hsian-Rong Tseng,
Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute,
University of California-Los Angeles
Dr. Tseng is professor in the Department of Molecular & Medical Pharmacology at UCLA. He also holds memberships of the California NanoSystems Institute, Crump Institute for Molecular Imaging and Institute for Molecular Medicine on the UCLA campus. Since he joined UCLA Pharmacology in 2003, Dr. Tseng’s group at UCLA has developed a series of nanotechnology- and microfluidics-enabled in vitro molecular diagnostic (IVMD) technologies. In collaboration with his physician colleagues, the goal of their joint team is to translate these new IVMD technologies from research bench to clinical practice.
NanoVelcro-Embedded MicroChips for Detection and Isolation of Circulating Tumor Cells
Friday, 13 September 2013 at 14:15
Add to Calendar ▼2013-09-13 14:15:002013-09-13 15:15:00Europe/LondonNanoVelcro-Embedded MicroChips for Detection and Isolation of Circulating Tumor CellsExosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com
This presentation will introduce a new type of cell-affinity assay that is capable of detecting circulating tumor cells (CTCs) in blood samples collected from metastatic cancer patients. Similar to most of the existing approaches, anti-EpCAM was grafted onto the surfaces to distinguish CTCs from the surrounding hematologic cells. The uniqueness of our technology is the use of nanostructured surfaces, which facilitates local topographical interactions between CTCs and substrates at the very first cell/substrate contacting time point. We demonstrated the ability of these nanostructured substrates to capture CTCs in whole blood samples with significantly improved efficiency and selectivity.
Abstract. Our team at UCLA has demonstrated a highly efficient, inexpensive CTC assay capable of detecting and isolating CTCs in blood samples collected from metastatic cancer patients. First, we pioneered a unique concept of “NanoVelcro” cell-affinity substrates, by which capture agent (antibodies or aptamers)-coated nanostructured surfaces were utilized to immobilize CTCs in a stationary device setting. Second, by integrating the NanoVelcro substrate with an overlaid microfluidic component that can generate vertical flows, further improved CTC capture efficiency (>85%) has been achieved as a result of the enhanced collisions between CTCs and the substrate. Side-by-side analytical validation using both artificial and patient CTC samples suggested that the sensitivity of our CTC Assay outperforms that of CellSearch. In order to further exploit CTC’s diagnostic value, we combine the use of NanoVelcro Chip with the Laser MicroDissection (LMD) technique to enable highly efficient and specific isolation of viable/preservative-free CTCs from patient blood samples. Ultimately, our goal is to carry out sequential molecular and functional analyses of the single CTCs harvested by our NanoVelcro-embedded microchips.
Add to Calendar ▼2013-09-12 00:00:002013-09-13 00:00:00Europe/LondonExosomes and Circulating Biomarkers Summit 2013Exosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2013-09-13 14:15:002013-09-13 15:15:00Europe/LondonNanoVelcro-Embedded MicroChips for Detection and Isolation of Circulating Tumor CellsExosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com
